{"disease":{"id":"non-valvular-atrial-fibrillation","name":"Non-valvular atrial fibrillation","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"chembl-chembl48361","indication_name":"Non-valvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Non-valvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"xarelto","indication_name":"Nonvalvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rivaroxaban","indication_name":"Nonvalvular atrial fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03087487","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":466991,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05321810","title":"Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":193565,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05471505","title":"Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding","phase":"","overall_status":"COMPLETED","enrollment_count":120722,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03374540","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","phase":"","overall_status":"COMPLETED","enrollment_count":78517,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05438888","title":"Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":77814,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03570047","title":"Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":73989,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03715725","title":"A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","phase":"","overall_status":"TERMINATED","enrollment_count":70000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05022758","title":"A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin","phase":"","overall_status":"COMPLETED","enrollment_count":45000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04297072","title":"Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists","phase":"","overall_status":"COMPLETED","enrollment_count":25000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05027061","title":"A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":11776,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02007655","title":"Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":6372,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04747496","title":"Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03234114","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":3746,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT01885598","title":"Eliquis Regulatory Post Marketing Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":3335,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03315650","title":"Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI","phase":"","overall_status":"COMPLETED","enrollment_count":1632,"lead_sponsor_name":"IHF GmbH - Institut für Herzinfarktforschung","has_results":false},{"nct_id":"NCT06168942","title":"A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination","phase":"NA","overall_status":"SUSPENDED","enrollment_count":1500,"lead_sponsor_name":"Biosense Webster, Inc.","has_results":false},{"nct_id":"NCT01884350","title":"Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1217,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03917563","title":"Registry to Evaluate Chinese Real-World Clinical Outcomes in Patients With AF Using the WATCHMAN Left Atrial Appendage Closure Technology","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05654272","title":"Development of CIRC Technologies","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT04586972","title":"Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;","phase":"","overall_status":"COMPLETED","enrollment_count":977,"lead_sponsor_name":"Gérond'if","has_results":false},{"nct_id":"NCT03746301","title":"Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation","phase":"","overall_status":"COMPLETED","enrollment_count":924,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04174859","title":"Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01598051","title":"Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":741,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05232643","title":"A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation","phase":"","overall_status":"RECRUITING","enrollment_count":720,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04519944","title":"Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":666,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT03887780","title":"A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)","phase":"","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04476147","title":"The Impact of Frailty on Thrombosis of Elderly Patients With NVAF （FTE-NVAF）","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04942873","title":"The Adherence to Oral Anticoagulant in Chinese Patients With NVAF","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07125417","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"OCEAN-SHD Study Group","has_results":false},{"nct_id":"NCT04356989","title":"Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function","phase":"","overall_status":"COMPLETED","enrollment_count":493,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05204212","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Prof. Dr. med. Ingo Eitel","has_results":false},{"nct_id":"NCT07396493","title":"A Prospective, Single-arm Study Evaluating the Endothelialization Effect and Timeline of AnchorMan® Left Atrial Appendage Occluder in Non-valvular Atrial Fibrillation Patients at High Risk of Stroke","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":306,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT02654470","title":"Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT02502396","title":"Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center","phase":"","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04429646","title":"LAMax Vs. Watchman LAAC Device for Subjects With Non-valvular AF to Reduce the Risk of Stroke","phase":"NA","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04829929","title":"Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Eclipse Medical Ltd.","has_results":false},{"nct_id":"NCT02422602","title":"Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05320627","title":"Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06862726","title":"Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation","phase":"PHASE4","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"Les Laboratoires des Médicaments Stériles","has_results":false},{"nct_id":"NCT04722679","title":"A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03515083","title":"Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Saint Luke's Health System","has_results":false},{"nct_id":"NCT02954237","title":"AMPLATZER™ Cardiac Plug Observational Post-Approval Study","phase":"","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Abbott Medical Devices","has_results":true},{"nct_id":"NCT03088072","title":"A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Scripps Health","has_results":false},{"nct_id":"NCT06606275","title":"The Safety and Effectiveness of Warfarin Vs Apixaban in Patients With NVAF/ VTE and ESKD on Dialysis","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Abu Dhabi Health Services Company","has_results":false},{"nct_id":"NCT06725355","title":"To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"HK inno.N Corporation","has_results":false},{"nct_id":"NCT05761704","title":"Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04096963","title":"Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT06189365","title":"Amplatzer Amulet China Post Market Study (PMS)","phase":"","overall_status":"TERMINATED","enrollment_count":50,"lead_sponsor_name":"Abbott Medical Devices","has_results":false},{"nct_id":"NCT05565599","title":"An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Biosense Webster, Inc.","has_results":false},{"nct_id":"NCT05567172","title":"Watchman FLX Pro CT Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}